Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis signs up to $5.2 billion licensing deal with Argo Biopharmaceutical for heart drugs
07:21am, Wednesday, 03'rd Sep 2025
Swiss drugmaker Novartis has signed a licensing and options deal with Argo Biopharmaceutical for up to $5.2 billion to gain access to its experimental cardiovascular drugs, the privately held biotech
Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases
07:00am, Wednesday, 03'rd Sep 2025
Agreement to explore Argo's Phase 2 ANGPTL3 in a combination trial in dyslipidemia with an option to license second-generation molecules in the pipeline License to an additional Argo siRNA candidate c
Novartis: Pipeline Progress And Buyback Drive Upside
04:16am, Wednesday, 03'rd Sep 2025
Novartis delivered strong Q2 results with 24% net income growth and robust sales from key drugs like Kisqali and Pluvicto, supporting our positive outlook. Despite generic competition and tariff conce
Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy
08:13am, Tuesday, 02'nd Sep 2025
Arrowhead Pharmaceuticals said on Tuesday it will receive up to $2 billion from Novartis for an exclusive worldwide license to its experimental therapy that targets neuromuscular conditions such as Pa
Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement
07:30am, Tuesday, 02'nd Sep 2025
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a global licensing and collaboration agreement with Novartis for ARO-SNCA, Arrowhead's precl
Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
11:00am, Saturday, 30'th Aug 2025
Basel, August 30, 2025 – Novartis today announced positive results from V-DIFFERENCE, a Phase IV study evaluating Leqvio® (inclisiran) compared to placebo, both administered on top of individually
New Novartis ESC data highlights strength of cardiovascular portfolio
01:15am, Monday, 18'th Aug 2025
PRESS RELEASE Two VictORION studies will highlight Leqvio's impact on patient quality of life, and as a cholesterol lowering monotherapy Lp(a)FRONTIERS APHERESIS study will assess effect of pelacarsen
Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm
07:23pm, Sunday, 17'th Aug 2025
Pharmaceutical companies regularly encounter substantial headwinds. Among the most significant are patent cliffs -- when therapies lose patent exclusivity, inviting cheaper generic or biosimilar compe
2 Dividend Stocks to Buy and Hold
08:15am, Friday, 15'th Aug 2025
We've seen several investing trends sweep through Wall Street in recent years, from excitement about the cannabis market to the artificial intelligence (AI) industry that's now dominating headlines. S
Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids 1,2 Patients treated
Novartis's Ianalumab Meets Key Goal in Late-Stage Trials for Autoimmune Disease
01:43am, Monday, 11'th Aug 2025
The pharma company said the drug has the potential to become the first and only targeted treatment approved for patients with Sjoegren's disease.
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease
01:20am, Monday, 11'th Aug 2025
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global Phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren's di
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease
01:15am, Monday, 11'th Aug 2025
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren's di
Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal
12:46pm, Wednesday, 06'th Aug 2025
Avidity Biosciences stock rocketed Wednesday on a report Novartis made an attempt to buy the rare disease-focused biotech company.
Novartis weighs deal for biotech Avidity Biosciences, FT reports
11:41am, Wednesday, 06'th Aug 2025
Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times reported, citing people familiar with the matter
